Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Semaglutide

Ozempic, Rybelsus, Wegovy

Quick Stats
Studies 78
Trials 100
Completed PHASE3 INTERVENTIONAL NCT04109547

A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and placebo (a dummy medicine). Researchers will test semaglutide to see how well it works compared to placebo. The study will also test if semaglutide is safe. Participants will either get semaglutide or placebo - which treatment is decided by chance. Participants will get 1 tablet a day to take with up to half a glass of water. Participants must take the tablet first thing in the morning on an empty stomach. After taking the tablet, participants must not eat or drink anything for at least 30 minutes. After the 30 minutes, participants can have their first meal of the day and take any other medicines they may need. The study will last for about 8 months (36 weeks). Participants will have 9 clinic visits and 2 phone calls with the study doctor. At all 9 of the clinic visits, participants will have blood samples taken. At 5 of the clinic visits, participants must arrive fasting. This means they cannot eat for 8 hours before the visit. It is fine to drink water up to 2 hours before the visit. This is for some of the blood samples that will be taken at the visit. Women cannot take part if pregnant, breastfeeding or planning to become pregnant during the study period.

Interventions

Name: Oral semaglutide
Type: DRUG
Description: Tablets to be taken once-daily for 26 weeks
Name: Placebo
Type: DRUG
Description: Tablets to be taken once-daily for 26 weeks

Primary Outcomes

Measure: Change From Baseline in Glycosylated Haemoglobin (HbA1c)
TimeFrame: Baseline (Week 0), Week 26
Description: Change from baseline (week 0) in HbA1c at week 26 is presented. The outcome data was evaluated based on the on-treatment without rescue medication observation period: from date of first dose of trial product following randomization up to the end date which was the first date of any of the following: the last dose of trial product plus 3 days or initiation of rescue medication.

Trial Information

NCT ID

NCT04109547

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE3

Sponsor

Novo Nordisk A/S

Last Updated

December 15, 2025